Daiichi Sankyo to launch products in Mexico via Ranbaxy
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is continuing to tap into the synergies provided by its acquisition of Ranbaxy Laboratories in order to expand its presence globally. The Japanese company expects to launch olmesartan medoxomil and prasugrel on the Mexican market through Ranbaxy's subsidiary, Ranbaxy Mexico.